Golimumab for the Treatment of Hidradenitis Suppurativa in Patients with Previous TNF-α Treatment Failure

Abstract

Hidradenitis suppurativa (HS) is a chronic inflammatory disease of the skin presenting with recurrent inflammatory nodules, cysts, abscesses, sinus tracts, and scar formation. Combined medical and surgical management is often required. The only Food and Drug Administration‒approved treatment for HS, adalimumab, is a mAb targeting TNF-α (Alikhan et al., 2019a, 2019b; Kimball et al., 2016). The use of golimumab, another fully humanized TNF-α inhibitor, has been described in two cases of HS with mixed results (Tursi, 2016; van der Zee and Prens, 2013).